Skip to main content
Clinical Trials/DRKS00025325
DRKS00025325
Recruiting
Not Applicable

on-interventional study on Therapeutic Drug Monitoring (TDM) in patients with renal cell carcinoma and on the feasibility of using Volumetric Absorptive Microsampling (VAMS) for sample collection (ON-TARGET) - ON-TARGET

Central European Society for Anticancer Drug Research (CESAR) e.V.0 sites80 target enrollmentJune 16, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C64
Sponsor
Central European Society for Anticancer Drug Research (CESAR) e.V.
Enrollment
80
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 16, 2021
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Central European Society for Anticancer Drug Research (CESAR) e.V.

Eligibility Criteria

Inclusion Criteria

  • Patients who are being treated with either axitinib or cabozantinib, who have full legal capacity and are linguistically, physically and mentally capable of completing the patient questionnaire independently, and who have provided written informed consent.

Exclusion Criteria

  • Patients with insufficient knowledge of the German language.

Outcomes

Primary Outcomes

Not specified

Similar Trials